<DOC>
	<DOCNO>NCT02601573</DOCNO>
	<brief_summary>This randomize , multi-site , open-label trial co-administration fixed-dose combination ( FDC ) elbasvir ( 50 mg ) /grazoprevir ( 100 mg ) ( EBR/GZR ) 400 mg sofosbuvir ( SOF ) , without ribavirin ( RBV ) , treatment-na√Øve ( TN ) treatment-experienced ( TE ) subject chronic Hepatitis C Virus ( HCV ) Genotype 3 ( GT3 ) infection compensate cirrhosis .</brief_summary>
	<brief_title>Elbasvir/Grazoprevir ( EBR/GZR ) Sofosbuvir ( SOF ) With Without Ribavirin ( RBV ) Cirrhotic Subjects With Chronic HCV GT3 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV RNA ( &gt; = 10,000 IU/mL peripheral blood ) screening document HCV GT3 ( evidence nontypeable mixed GT infection ) compensate cirrhosis liver liver image within 6 month Day 1 evidence hepatocellular carcinoma ( HCC ) either HCV TN TE ( i.e. , document prior virologic failure intolerance peginterferon/ribavirin ) otherwise healthy determine medical history , physical examination , electrocardiogram ( ECG ) , clinical laboratory measurement compensate cirrhosis liver TN TE ( i.e. , document prior virologic failure intolerance peginterferon/ribavirin ) reproductive potential , agrees impregnate partner become pregnant least 2 week prior first dose study drug , 7 month final dose study drug ( longer dictate local regulation ) previously receive one dos directacting antiviral ( DAA ) evidence decompensated liver disease coinfected hepatitis B ( hepatitis B surface antigen [ HBsAg ] positive ) recent ( within 5 year ) history malignancy evaluation HCC suspect malignancy currently participate ( within past 30 day ) study investigational compound clinicallyrelevant drug alcohol abuse within past 12 month screen female pregnant breastfeed male whose female partner is/are pregnant following : organ transplant poor venous access history gastric surgery malabsorption disorder current history clinically significant cardiac abnormality dysfunction chronic pulmonary disease hemoglobinopathy history hospitalization within 3 month prior enrollment medical surgical condition may result need hospitalization course study condition requiring , likely require , chronic systemic administration corticosteroid , tumor necrosis factor ( TNF ) antagonists , immunosuppresant drug course study condition , prestudy laboratory ECG abnormality , history illness , could confound result study pose additional risk administer study drug opinion investigator lifethreatening serious AE ( SAE ) screen period evidence history chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>